Robert James  Wills net worth and biography

Robert Wills Biography and Net Worth

Director of Alpha Cognition

Dr. Wills serves as Chairman of the Board of Milestone Pharmaceuticals, Inc. (Nasdaq: MIST), serves on as a board member at Parion Sciences, Inc., and a board member at Oncternal Therapeutics (Nasdaq: ONCT). Dr Wills previously served as the Chairman of the Board of CymaBay Therapeutics (Nasdaq: CBAY) prior to the acquisition by Gilead Sciences, Inc. in March 2024, and served as Executive Chairman of GTx, Inc. from 2015-2019. Prior to that he spent over 25 years at Johnson & Johnson. His roles included Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson and as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. Dr. Wills holds a B.S. in Biochemistry and a M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.

What is Robert James Wills' net worth?

The estimated net worth of Robert James Wills is at least $306.93 thousand as of August 21st, 2026. Wills owns 32,241 shares of Alpha Cognition stock worth more than $306,934 as of September 7th. This net worth approximation does not reflect any other assets that Wills may own. Learn More about Robert James Wills' net worth.

How do I contact Robert James Wills?

The corporate mailing address for Wills and other Alpha Cognition executives is 20073 FIDDLERS GREEN, FRISCO, TX, 75036. Alpha Cognition can also be reached via phone at (858) 344-4375 and via email at [email protected]. Learn More on Robert James Wills' contact information.

Has Robert James Wills been buying or selling shares of Alpha Cognition?

During the past quarter, Robert James Wills has bought $96,200.00 in shares of Alpha Cognition stock. Most recently, on Friday, August 21st, Robert James Wills bought 10,000 shares of Alpha Cognition stock. The stock was acquired at an average cost of $9.62 per share, with a total value of $96,200.00. Following the completion of the transaction, the director now directly owns 32,241 shares of the company's stock, valued at $310,158.42. Learn More on Robert James Wills' trading history.

Who are Alpha Cognition's active insiders?

Alpha Cognition's insider roster includes Lauren D'Angelo (COO), Phillip Mertz (Director), and Robert Wills (Director). Learn More on Alpha Cognition's active insiders.

Are insiders buying or selling shares of Alpha Cognition?

In the last year, Alpha Cognition insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $116,360.00. The most recent insider tranaction occured on August, 21st when Director Robert James Wills bought 10,000 shares worth more than $96,200.00. Insiders at Alpha Cognition own 8.6% of the company. Learn More about insider trades at Alpha Cognition.

Information on this page was last updated on 8/21/2026.

Robert James Wills Insider Trading History at Alpha Cognition

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2026Buy10,000$9.62$96,200.0032,241View SEC Filing Icon  
8/18/2025Buy15,000$8.49$127,350.0015,000View SEC Filing Icon  
See Full Table

Robert James Wills Buying and Selling Activity at Alpha Cognition

This chart shows Robert James Wills's buying and selling at Alpha Cognition by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alpha Cognition Company Overview

Alpha Cognition logo
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $9.52
Low: $9.10
High: $9.54

50 Day Range

MA: $8.63
Low: $6.81
High: $9.75

2 Week Range

Now: $9.52
Low: $4.50
High: $10.14

Volume

45,936 shs

Average Volume

171,622 shs

Market Capitalization

$207.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.32